GPT and Lymphadenopathy: Nine patients (4·9%) had 17 serious AEs that investigators suspected to be related to deferasirox treatment, including gastrointestinal disorders (n =3), sickle cell crisis (n =2), lymphadenopathy (n =1), tinnitus (n=1), granuloma (n =1), tuberculosis (n =1), spontaneous abortion (n =1), pulmonary thrombosis (n =1), increased alanine aminotransferase (ALT; n =1), increased aspartate aminotransferase (AST; n =1), increased blood alkaline phosphatase (n= 1), increased blood amylase (n =1), increased blood bilirubin (n =1), increased lipase (n =1) and increased transaminases (n =1).